BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23136545)

  • 21. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
    Abe M; Okada K; Soma M; Matsumoto K
    Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
    Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
    Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis.
    Opatrný K; Krouzecký A; Wirth J; Vít L; Eiselt J
    Artif Organs; 1998 Oct; 22(10):816-20. PubMed ID: 9790077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness.
    Yuen D; Richardson RM; Fenton SS; McGrath-Chong ME; Chan CT
    ASAIO J; 2005; 51(3):236-41. PubMed ID: 15968953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress.
    Joksimovic Jovic J; Antic S; Nikolic T; Andric K; Petrovic D; Bolevich S; Jakovljevic V
    Oxid Med Cell Longev; 2022; 2022():9598211. PubMed ID: 35464768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.
    González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á
    BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid peroxidation and antioxidant enzymes in children on maintenance dialysis.
    Zwołińska D; Grzeszczak W; Szczepańska M; Kiliś-Pstrusińska K; Szprynger K
    Pediatr Nephrol; 2006 May; 21(5):705-10. PubMed ID: 16518626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selenium and glutathione levels, and glutathione peroxidase activities in blood components of uremic patients on hemodialysis supplemented with selenium and treated with erythropoietin.
    Zachara BA; Adamowicz A; Trafikowska U; Trafikowska A; Manitius J; Nartowicz E
    J Trace Elem Med Biol; 2001; 15(4):201-8. PubMed ID: 11846008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
    Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
    Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment.
    Zachée P; Ferrant A; Daelemans R; Coolen L; Goossens W; Lins RL; Couttenye M; De Broe ME; Boogaerts MA
    Nephron; 1993; 65(2):288-93. PubMed ID: 8247195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication.
    Zachée P; Ferrant A; Daelemans R; Goossens W; Boogaerts MA; Lins RL
    Nephron; 1995; 71(3):343-9. PubMed ID: 8569984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hemodialysis period on levels of blood trace elements and oxidative stress.
    Koca T; Berber A; Koca HB; Demir TA; Koken T
    Clin Exp Nephrol; 2010 Oct; 14(5):463-8. PubMed ID: 20589406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.